A Phase 3 interventional study of iLet Bionic Pancreas System (BP) and Usual Care (UC) in Cystic Fibrosis-related Diabetes, sponsored by Jaeb Center for Health Research. Active, not recruiting at 16 sites in United States. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Jaeb Center for Health Research · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.
Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 87th largest by planned enrollment of the 517 interventional ones that give a count, is one of 30 that started in 2024, is one of 100 in phase 3, reaches primary completion later than 47 of the 108 other live ones, and was the 669th registered.
1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Aimmune Nestlé Health Science US R&D, LLC · Sites in United States, Bulgaria, Hungary and 4 more countries
Ages 18–85
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 3–18
Ghady Haidar · Sites in United States
Ages 18+
Anagram Therapeutics, Inc. · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.
This study: 14 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
717 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 109 · Phase 2 143 · Phase 3 108 · Phase 4 47
First in 1988; this study’s year is marked. 30 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 36 across the 517 interventional studies, 80 across the 193 observational. Of the 569 that completed or were terminated, 263 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
250 of 717 have an industry lead sponsor. The 10 most frequent:
Jaeb Center for Health Research is the lead sponsor of 129 studies on the registry; 16 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Jaeb Center for Health Research has 3 studies filed under Cystic Fibrosis — fewer than ten, so there is no comparison to draw.
43 of the studies in Cystic Fibrosis with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06413368Phase 3Children's Hospital Los AngelesMaralixibat in Patients With Cystic Fibrosis and Constipation | 2027-06-30 |
| NCT06449677Phase 3Jaeb Center for Health ResearchBionic Pancreas in CFRD | 2027-06-30 |
| NCT06996951Phase 3Indiana UniversitySinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy | 2027-07 |
| NCT06237335ReCode TherapeuticsA Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 43 to your calendar (.ics) → With an account.
Among the 717 studies in Cystic Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using their usual care insulin delivery method and continuous glucose monitoring (CGM) during a 13-week study period in individuals ≥14 years old with cystic fibrosis-related diabetes (CFRD). After 13 weeks, participants will continue in a 13-week Extension Phase in which the BP group will continue to use the BP system and the Usual Care group will initiate use of the BP system.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:
Able to speak and read English sufficient to understand the pump user interface and provide written materials for safe operation of the BP
Exclusion
Have started or stopped a CFTR modulator in the 4 weeks prior to screening.
Lung or liver transplant within one year prior to screening. If they have had a transplant more than a year ago, but they:
Presence of a medical condition or use of a medication that, in the judgment of the investigator, clinical protocol chair, or medical monitor, could compromise the results of the study or the safety of the participant. Conditions to be considered by the investigator may include the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to the Usual Care (UC) group will use their existing insulin delivery method in conjunction with a study CGM during the first 13-week of the study (RCT phase). The UC group will then initiate use of the BP System for the remaining 13 weeks of the study (Extension Phase).
Device: iLet Bionic Pancreas System (BP) · Device: Usual Care (UC)
Participants randomized to the intervention group will use the BP group using the iLet Bionic Pancreas System (BP) and continuous glucose monitoring (CGM) during the first 13-week of the study (RCT phase). After the RCT phase, participants will continue in a 13-week Extension Phase in which the BP group will continue to use the BP system.
Device: iLet Bionic Pancreas System (BP)
The iLet Bionic Pancreas System (BP) consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls insulin delivery based on glucose values obtained by communicating with a CGM sensor.
Usual Care consists in the participant existing insulin therapy (prior to enrollment) in conjunction with a study CGM. Existing insulin therapies are defined as multiple daily injections of insulin (MDI) or use of an insulin pump.
CGM-measured Time In Target Range of 70-180 mg/dL (TIR)
CGM-measured time in target range of 70-180 mg/dL (TIR)
Time frame: 13 weeks
CGM-measured Time In Range <54 mg/dL
CGM-measured time in range \<54 mg/dL
Time frame: 13 weeks
CGM-measured Mean Glucose
Average glucose value measured by CGM
Time frame: 13 weeks
CGM-measured Time In Range >180 mg/dL
CGM-measured time in range \>180 mg/dL
Time frame: 13 weeks
CGM-measured Time In Range >250 mg/dL
CGM-measured time in range \>250 mg/dL
Time frame: 13 weeks
HbA1c At 13 Weeks
HbA1c at 13 weeks
Time frame: 13 weeks
Glucose Variability Measured With the Standard Deviation (SD)
Glucose variability measured with the standard deviation (SD)
Time frame: 13 weeks
CGM-measured Time In Range <70 mg/dL
CGM-measured time in range \<70 mg/dL
Time frame: 13 weeks
Glucose Variability With the Coefficient of Variation (CV)
Glucose variability with the coefficient of variation (CV)
Time frame: 13 weeks
HbA1c <7.0% At 13 Weeks
HbA1c \<7.0% at 13 weeks
Time frame: 13 weeks
HbA1c <7.0% At 13 Weeks In Participants With Baseline HbA1c >7.5%
HbA1c \<7.0% at 13 weeks in participants with baseline HbA1c \>7.5%
Time frame: 13 weeks
HbA1c <8.0% At 13 Weeks
HbA1c \<8.0% at 13 weeks
Time frame: 13 weeks
HbA1c Improvement From Baseline To 13 Weeks >0.5%
HbA1c improvement from baseline to 13 weeks \>0.5%
Time frame: 13 weeks
HbA1c Improvement From Baseline To 13 Weeks >1.0%
HbA1c improvement from baseline to 13 weeks \>1.0%
Time frame: 13 weeks
HbA1c Improvement From Baseline To 13 Weeks >1.0% Or HbA1c <7.0% At 13 Weeks
HbA1c improvement from baseline to 13 weeks \>1.0% or HbA1c \<7.0% at 13 weeks
Time frame: 13 weeks
CGM-measured Time In Tight Range (TITR) 70-140 mg/dL
CGM-measured time in tight range (TITR) 70-140 mg/dL
Time frame: 13 weeks
CGM-measured Area Over the Curve (70 mg/dL)
CGM-measured area over the curve (70 mg/dL)
Time frame: 13 weeks
CGM-measured Low Sensor Glucose Events
CGM-measured low sensor glucose events
Time frame: 13 weeks
CGM-measured Prolonged High Sensor Glucose Events
CGM-measured prolonged high sensor glucose events
Time frame: 13 weeks
CGM-measured Time >300 mg/dL
CGM-measured time \>300 mg/dL
Time frame: 13 weeks
CGM-measured Area Under the Curve (180 mg/dL)
CGM-measured area under the curve (180 mg/dL)
Time frame: 13 weeks
CGM-measured TIR >70%
CGM-measured TIR \>70%
Time frame: 13 weeks
CGM-measured TIR Improvement From Baseline To 13 Weeks ≥5%
CGM-measured TIR improvement from baseline to 13 weeks ≥5%
Time frame: 13 weeks
CGM-measured TIR Improvement From Baseline To 13 Weeks ≥10%
CGM-measured TIR improvement from baseline to 13 weeks ≥10%
Time frame: 13 weeks
CGM-measured Time <70 mg/dL <4%
CGM-measured time \<70 mg/dL \<4%
Time frame: 13 weeks
CGM-measured Time <54 mg/dL <1%
CGM-measured time \<54 mg/dL \<1%
Time frame: 13 weeks
CGM-measured TIR >70% and Time <54 mg/dL <1%
CGM-measured TIR \>70% and time \<54 mg/dL \<1%
Time frame: 13 weeks
CGM-measured Improvement In TIR By >10% Without An Increase In Time <54 mg/dL By >0.5%
CGM-measured improvement in TIR by \>10% without an increase in time \<54 mg/dL by \>0.5%
Time frame: 13 weeks
Type 1 Diabetes Distress Scale (T1-DDS)
The T1-DDS is to evaluate diabetes-related emotional distress in type 1 diabetic patients. The scale consists of 17 items, contains 4 domains (emotional burden subscale, physician-related subscale, regimen-related distress subscale, and diabetes-related interpersonal distress). Each item is rated on a 6-point Likert scale from 1 (no problem) to 6 (serious problem). Patients with higher scores are considered with more distress
Time frame: Screening, 13 weeks
Problem Areas In Diabetes - Teens (PAID-T) and Parents of Teens (P-PAID-T)
The PAID-T and P-PAID-T questionnaires consist of 26 items that are scored on a 6-point Likert scale from 1-2 (not a problem) to 5-6 (serious problem). The derived total score (26 questions) ranges between 26 and 156, where high scores represent a higher burden
Time frame: Screening, 13 weeks
Hypoglycemia Confidence Scale (≥18)
A person-reported outcome measure (PROM) that examines the degree to which people with diabetes feel able, secure, and comfortable regarding their ability to stay safe from hypoglycemic-related problems (9-item scale with 4 choices that range from 1 (Not Confident At All) to 4 (Very Confident)). The total score can range from 1 to 4, with a higher score indicating a better outcome
Time frame: Screening, 13 weeks
INSPIRE Survey (Insulin Delivery Systems: Perceptions, Ideas, Reflections, and Expectations)
INSPIRE 5-point Likert scale from strongly agree to strongly disagree, along with an N/A option
Time frame: Screening, 13 weeks
Fear of Hypoglycemia Survey (HFS-II) - Total Score, 2 Subscales and 4 Factor Scores
Fear of Hypoglycemia Survey (HFS-II) - total score, 2 subscales and 4 factor scores: Behavior (avoidance, maintain high BG), Worry (helplessness, social consequences)
Time frame: Screening, 13 weeks
The EuroQol 5 Dimension 5 Level (EQ-5D-5L)
The EQ-5D-5L is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical appraisal. The EQ-5D evaluates 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) using a 5-level severity scale from 1 (no problems) to 5 (extreme problems), and is converted to a single summary index by applying a formula that essentially attaches weight to each of the levels in each dimension. The visual analogue score (VAS) evaluates the health condition assessed by patients to producae a quantitive measure of health outcome that reflects the patient's own judgement on a range from "the worst health you can imagine" to "the best health you can imagine"
Time frame: Screening, 13 weeks
World Health Organization Well-being Index (WHO-5)
WHO-5 is a 5-item questionnaire of the World Health Organization that measures health related quality of life. Each item is scored on a scale of 0 (at no time) to 5 (all the time). Higher scores indicate greater well-being
Time frame: Screening, 13 weeks
Perceived Benefits and Burdens of AID Systems
A 35-item survey that assesses user expectations of a hybrid closed loop AID system using a 5-point Likert scale from "strongly disagree" to "strongly agree"
Time frame: Screening, 13 weeks
Total Daily Insulin (Units/kg)
Total daily insulin (Units/kg)
Time frame: 13 weeks
Percentage of Total Insulin Delivered Via Basal
Percentage of total insulin delivered via basal
Time frame: 13 weeks
Percentage of Total Insulin Delivered Via Bolus
Percentage of total insulin delivered via bolus
Time frame: 13 weeks
Weight
Weight
Time frame: 13 weeks
Body Mass Index (BMI)
Body Mass Index (BMI)
Time frame: 13 weeks
Number of Severe Hypoglycemia (SH) Events and SH Event Rate Per 100 person-years
Number of Severe Hypoglycemia (SH) events and SH event rate per 100 person-years
Time frame: 13 weeks
Number of Diabetes Ketoacidosis (DKA) Events and DKA Event Rate Per 100 person-years
Number of Diabetes Ketoacidosis (DKA) events and DKA event rate per 100 person-years
Time frame: 13 weeks
Number of Other Serious Adverse Events (SAEs other than SH events and DKA events)
Number of Other Serious Adverse Events (SAEs other than SH events and DKA events)
Time frame: 13 weeks
Number of Unanticipated Adverse Device Effects (UADE)
Number of Unanticipated Adverse Device Effects (UADE)
Time frame: 13 weeks
Number of Infusion Set Failures
Number of infusion set failures
Time frame: 13 weeks
Other Device Malfunctions/Device Issues
Number of other malfunctions/issues related to the study device
Time frame: 13 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Jun 2027, 33 months after the start.
Of 67 phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 39. This study's planned 33 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Sep 2026 → Jun 2027 and completion May 2027 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jaeb Center for Health Research →